Physician profile
Michael Atwell
NPI 1467958264
$4,693.85
in general payments reported to CMS, 2019-2025
18 companies · $2,120 in 2025
The $2,120 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $185 · 2021: $510 · 2022: $393 · 2023: $726 · 2024: $637 · 2025: $2,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,084 · Travel and Lodging: $1,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,084.00 |
| Travel and Lodging | $1,398.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,814.44 | 2019-2025 | General - Kidney Stone Disease, Flexible Probe, Ams 700 |
| Axonics, INC. | $473.15 | 2022-2024 | Bulkamid, Axonics |
| Coloplast Corp | $291.18 | 2021-2022 | |
| Calyxo, INC. | $200.75 | 2025 | Cvac Aspiration System |
| Valencia Technologies Corporation | $200.44 | 2024 | Ecoin Device Kit |
| Medtronic, INC. | $114.15 | 2022 | |
| Innovation Technologies INC | $106.01 | 2022-2023 | Irrisept |
| Procept Biorobotics Corporation | $102.54 | 2025 | |
| Janssen Scientific Affairs, LLC | $66.97 | 2025 | Erleada |
| Ferring Pharmaceuticals INC. | $61.53 | 2024-2025 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $60.98 | 2024-2025 | |
| Astellas Pharma US INC | $47.44 | 2025 | Xtandi |
| Sumitomo Pharma America, INC. | $38.31 | 2024-2025 | Orgovyx, Gemtesa |
| Urogen Pharma, INC. | $32.03 | 2023 | Jelmyto |
| Merck Sharp & Dohme LLC | $25.37 | 2025 | Keytruda Qlex, Keytruda |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $21.48 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $19.83 | 2024 | Imjudo |
| Pfizer INC. | $17.25 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Atwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.